|Bid||1.4000 x 3100|
|Ask||1.4500 x 3100|
|Day's Range||1.2800 - 1.5500|
|52 Week Range||1.1700 - 11.3000|
|Beta (5Y Monthly)||1.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.25|
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 24-25, 2020 in a virtual format.The details for the poster presentation are as follows:Date and Time: October 24, 2020, 9:00 a.m. ET Abstract Title: PDK1 inhibitor SNS-510 shows synergy with standard cancer therapies in solid tumor and hematologic cancer models Session Name: Molecular Targeted Agents Publication Number: 163 The full abstract can be viewed here, and the poster will be made available on the Sunesis website at the time of the presentation.About Sunesis PharmaceuticalsSunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including first-in-class PDK1 inhibitor SNS-510. SNS-510 is in IND-enabling studies and vecabrutinib has completed a Phase 1b trial in patients with advanced B cell malignancies.For additional information on Sunesis, please visit www.sunesis.com.SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.Forward-Looking StatementsThis press release contains forward-looking statements, including statements related to Sunesis’ continued development and potential of its kinase inhibitor pipeline, including SNS-510; the therapeutic potential of SNS-510 and vecabrutinib. Words such as “expect,” “will,” “look forward,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These risk factors are discussed under "Risk Factors" in Sunesis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and Sunesis' other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Sunesis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902 Par Hyare Sunesis Pharmaceuticals Inc. 650-266-3784
The drugmaker is having to take a last-resort measure to keep its shares listed on the Nasdaq stock exchange.
During Q2, Sunesis Pharmaceuticals's (NASDAQ: SNSS) reported sales totaled $0.00. Despite a 9.43% in earnings, the company posted a loss of $6.34 million. Sunesis Pharmaceuticals collected $120.00 thousand in revenue during Q1, but reported earnings showed a $5.80 million loss.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Sunesis Pharmaceuticals posted an ROCE of -0.39%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on SNSSROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Sunesis Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.For Sunesis Pharmaceuticals, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q2 Earnings Insight Sunesis Pharmaceuticals reported Q2 earnings per share at $-0.06/share, which did not meet analyst predictions of $-0.06/share.See more from Benzinga * Recap: Sunesis Pharmaceuticals Q2 Earnings * Earnings Scheduled For August 11, 2020 * Earnings Preview for Sunesis Pharmaceuticals(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.